New York, USA – July 1, 2020 – Creative Biolabs has been supplying standard products and professional services associated with biotechnology, to global clients who are working on medicine manufacturing or development of novel therapeutics. In the face of the COVID-19 that is rampaging throughout the world, scientists at Creative Biolabs spare no efforts to leveraging valuable resources and offering best-in-line antibody products for the study of this novel coronavirus.
It seems that the COVID-19 will still be rampaging till the end of 2020, according to researchers. By now, the confirmed cases amount to over 10.5M, with 511K deaths, and 5.34M recovered, updated on July 1, 2020. The epidemic caused by coronavirus is not the first time in history. People can still remember the health crisis in 2002 and 2012, the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). Creative Biolabs has accumulated rich experience after studying the coronavirus groups and gathered valuable resources, and successfully discovered various SARS, MERS and other anti-viral antibodies for research use. The scientist team is fully competent to help researchers with their projects regarding the novel SARS-CoV-2.
Firstly discovered in 1968, coronavirus is a group of viruses with a crown-like shape on the surface. Up to now, there are 7 types of coronaviruses known to infect human beings, which can be categorized as a, ß, ?, and d. SARS, MERS and 2019-nCoV belong to the ß genus. Previous studies pave the way for analyzing SARS-CoV-2 that it infects the cell of the hosts after the combination of the ACE2 receptor with the spike protein (S protein) on the surface, the same way as that of SARS-CoV entering human cells. To conclude, the SARS-CoV-2 spike protein is regarded as a crucial biomarker of COVID-19 diagnosis, and a target of drugs and vaccines that are in preclinical/clinical stages.
Creative Biolabs has leveraged useful resources instantly and is capable of offering SARS-CoV-2 S antibodies that come from common hosts like human, mouse, and rabbit, and apply to various lab tests, like ELISA, FC, ICC/IF, etc., which can play a role in the ongoing studies.
Apart from the aforesaid S protein antibodies, Creative Biolabs owns a comprehensive list of anti-SARS-CoV-2 antibodies to assist with the research and development of drug and vaccine candidates, including but not limited to antibodies targeting genes like N, S1/S2, and ORF7a.
“We have received many inquiries on the antibodies for COVID-19,” said the head of Creative Biolabs, “and we’re well prepared to accommodate orders with our enough products in stock for quick delivery.” It’s worthy of mentioning that under the current crisis, the devotion of those scientists is really valuable.
More information about the antibodies can be accessed at https://www.antibody-creativebiolabs.com.
About Creative Biolabs
Creative Biolabs has spent years of concentration on the study of utilizing antibodies to develop novel therapeutics, and has gathered rich experience and abundant resources to support research on cancer, COVID-19, and other diseases. The product portfolio covers antibodies and antibody arrays for research use, which are offered at competitive price in the industry.